Roche lifted the Swiss drugmaker’s 2019 sales target for the third time during the year, helped by newer medicines and as China bought more cancer drugs to treat a disease blamed for a quarter of the nation’s annual deaths.
Indivior Plc raised the company’s full-year 2019 forecasts as the embattled British drugmaker’s best-selling opioid addiction drug Suboxone fared better than expected in the face of competition from copycats.
Five Prime Therapeutics Inc. will eliminate 70 jobs while undergoing a restructuring to extend the company’s cash runway.
Southern California-based Sienna Biopharmaceuticals filed for bankruptcy, which sent share prices tumbling more than 73 percent.
Novo Nordisk’s sales forecast for 2019 was raised due to growing demand for obesity products and a new injectable treatment for diabetes, which is now the company’s growth engine as insulin sales decline.
Teva Pharmaceutical Industries reported a smaller-than-expected drop in second-quarter 2019 profit and said the chief financial officer was leaving the company.
Sanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.
Despite concerns about potential competition from recently approved and available European biosimilars to Humira, AbbVie was able to stave off some of the losses expected during Q2 2019.
Roche lifted the company’s full-year sales outlook after revenue in first-half 2019 rose 18 percent, helped by newer drugs including the MS medicine Ocrevus and the cancer immunotherapy Tecentriq.
Biogen Inc. reported better-than-expected second quarter 2019 profit and raised the company’s full-year earnings forecast, driven by higher sales of the top-selling multiple sclerosis drug Tecfidera and lower taxes.